Literature DB >> 16778317

Leishmania/HIV co-infections in the second decade.

Israel Cruz1, Javier Nieto, Javier Moreno, Carmen Cañavate, Philippe Desjeux, Jorge Alvar.   

Abstract

Leishmania-HIV co-infection has been globally controlled in Southern Europe since 1997 because of highly active anti retroviral therapy (HAART), but it appears to be an increasing problem in other countries such as Ethopia, Sudan, Brazil or India where both infections are becoming more and more prevalent. Most of the scientific background on Leishmania/HIV co-infection has been dropped from the Mediterranean experience and although the situations among countries are not fully comparable, it is of high importance to take advantage of this knowledge. In this review several aspects of the Leishmania/HIV co-infection are emphasized viz., epidemiological features, new ways of transmission, pathogenesis, clinical outcome, diagnosis, treatment and secondary prohylaxis. An extensive review of the literature on Leishmania/HIV co-infection has allowed the inclusion of a comprehensive and updated list of bibliographical references.

Entities:  

Mesh:

Year:  2006        PMID: 16778317

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  60 in total

1.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

2.  Probing elongating and branching β-D-galactosyltransferase activities in Leishmania parasites by making use of synthetic phosphoglycans.

Authors:  Olga V Sizova; Andrew J Ross; Irina A Ivanova; Vladimir S Borodkin; Michael A J Ferguson; Andrei V Nikolaev
Journal:  ACS Chem Biol       Date:  2011-04-11       Impact factor: 5.100

3.  First case of visceral leishmaniasis caused by Leishmania martiniquensis.

Authors:  Bernard Liautaud; Nicolas Vignier; Charline Miossec; Yves Plumelle; Moumini Kone; Delphine Delta; Christophe Ravel; André Cabié; Nicole Desbois
Journal:  Am J Trop Med Hyg       Date:  2014-11-17       Impact factor: 2.345

4.  Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Authors:  Rati Tandon; Sharat Chandra; Rajendra Kumar Baharia; Sanchita Das; Pragya Misra; Awanish Kumar; Mohammad Imran Siddiqi; Shyam Sundar; Anuradha Dube
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

5.  Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid.

Authors:  Néstor M Carballeira; Michelle M Cartagena; Christopher Fernández Prada; Celia Fernández Rubio; Rafael Balaña-Fouce
Journal:  Lipids       Date:  2009-09-30       Impact factor: 1.880

6.  Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

Authors:  Pranav Kumar; Robert Lodge; Nathalie Trudel; Michel Ouellet; Marc Ouellette; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30

7.  The Leishmania amazonensis TRF (TTAGGG repeat-binding factor) homologue binds and co-localizes with telomeres.

Authors:  Marcelo S da Silva; Arina M Perez; Rita de Cássia V da Silveira; Camila E de Moraes; Jair L Siqueira-Neto; Lucio de H Freitas; Maria Isabel N Cano
Journal:  BMC Microbiol       Date:  2010-05-07       Impact factor: 3.605

8.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09

10.  Activity of hydroxyurea against Leishmania mexicana.

Authors:  Hugo Martinez-Rojano; Javier Mancilla-Ramirez; Laura Quiñonez-Diaz; Norma Galindo-Sevilla
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.